Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 17/20 | 0.51 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.51 |
| ▸ | AKT1 | P31749 | 7/20 | 0.45 |
| ▸ | MTOR | P42345 | 5/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL857119 | 0.88 | PIK3CA (0.67) | PIK3CAMAP3K12AKT1MTORPIK3R1 | |
| SCHEMBL855764 | 0.85 | PIK3CA (0.64) | PIK3CAMAP3K12AKT1MTORMAPT | |
| SCHEMBL10327761 | 0.81 | PIK3CA (0.67) | PIK3CAMAP3K12AKT1MTORPIK3R1 | |
| SCHEMBL10328178 | 0.77 | PIK3CA (0.55) | PIK3CAMAP3K12AKT1MTORPIK3R1 | |
| SCHEMBL857404 | 0.74 | PIK3CA (0.52) | PIK3CAMAP3K12AKT1MTORPIK3R1 | |
| SCHEMBL854991 | 0.73 | PIK3CA (0.80) | PIK3CAMAP3K12AKT1MTORPIK3R1 | |
| SCHEMBL13492026 | 0.72 | PIK3CA (0.53) | PIK3CAMAP3K12AKT1MTORPIK3R1 | |
| SCHEMBL14135360 | 0.72 | PIK3CA (0.67) | PIK3CAMAP3K12AKT1MTORMAPT | |
| SCHEMBL26025308 | 0.70 | PIK3CA (0.57) | PIK3CAAKT1MTORMAPTTSHR | |
| SCHEMBL10327890 | 0.69 | PIK3CA (1.00) | PIK3CAMAP3K12AKT1MTORPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173647-B2 | PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-8173647-B2 | PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-8173647-B2 | PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| EP-2118087-B1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-03-28 | — | — | EP | disclosed |
| EP-2118087-B1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-03-28 | — | — | EP | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| WO-2008098058-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | PI4KA, PI4KB, PI4K2A | PIK3CA 5/4885MAP3K12 60/4885AKT1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.